Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) EPS (Weighted Average and Diluted) (2019 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.8 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 28.57% to -$0.8 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.93 through Dec 2025, up 58.67% year-over-year, with the annual reading at -$2.52 for FY2025, 32.08% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.8 at Creative Medical Technology Holdings, down from -$0.48 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $11.18 in Q1 2021, with the low at -$4.16 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.02, with a median of -$0.53 recorded in 2022.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 231897.04% in 2021, while the deepest fall reached 12400.0% in 2021.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$4.16 in 2021, then surged by 87.26% to -$0.53 in 2022, then crashed by 125.0% to -$1.19 in 2023, then rose by 6.08% to -$1.12 in 2024, then grew by 28.57% to -$0.8 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.8, -$0.48, and -$0.48 for Q4 2025, Q3 2025, and Q2 2025 respectively.